Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Recursion Pharmaceuticals (NASDAQ: RXRX) is not the most famous artificial intelligence (AI) stock on the market, but the ...

But too few firms think deeply about what they want their culture to be, or about how to embed it. As the latest episode of ...

Eli Lilly already has a couple of top GLP-1 drugs that help patients with diabetes (Mounjaro) and weight loss (Zepbound), but ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

No, Donald Trump was not the focus of attention this week, even though the US president invited people to a parade to ...

With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways ...

Healthcare Summit 2025 hosted by IISc attracts 500 global leaders to focus on future of sector: Our Bureau, Bengaluru Monday, June 16, 2025, 14:45 Hrs [IST] Indian Institute of Sc ...

Gov. Josh Shapiro’s administration plans to save money by cutting poor patients’ access to expensive weight-loss drugs like ...

Novo Nordisk has rebounded strongly in 2025, backed by solid financials despite earlier setbacks and competitive risks. See ...

The reason Novo Nordisk is losing patent protection is because it wouldn't pay a couple hundred bucks. In 2019, the Canadian patent office sent a letter saying it hadn't received Novo Nordisk's annual ...

Health workers have long relied on Body Mass Index to gauge whether people are within a healthy weight range. Now, top researchers have made the case for a new way to understand and diagnose obesity.